Mylan releases Aromasin generic in U.S.

Print Friendly, PDF & Email
PITTSBURGH — Mylan N.V. has launched exemestane tablets 25 mg, a breast cancer medication, in the United States.

Mylan said its exemestane product is a generic version of Aromasin tablets from Pfizer Inc.

Exemestane is indicated for the treatment of certain types of breast cancer in women after menopause. The medication works by reducing estrogen levels to slow the growth of breast tumors.

Mylan noted that it’s the largest supplier of cancer medicines by volume in the United States and the release of exemestane tablets 25 mg adds to its robust oncology franchise.

Exemestane tablets (25 mg) totaled U.S. sales of approximately $100 million for the 12 months ended Jan. 31, according to IMS Health data reported by Mylan.



Comments are closed.